Clinical trials
Thyroid Diseases trials in Taiwan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
15 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 6 |
| Completed | 5 |
| Recruiting | 2 |
| Active, not recruiting | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Taiwan University Hospital | 3 |
| Chang Gung Memorial Hospital | 2 |
| Fu Jen Catholic University | 2 |
| Eli Lilly and Company | 1 |
| Far Eastern Memorial Hospital | 1 |
| HAN Biomedical Inc | 1 |
| Hoffmann-La Roche | 1 |
| Kaohsiung Medical University Chung-Ho Memorial Hospital | 1 |
| Kaohsiung Veterans General Hospital. | 1 |
| Pierre Fabre Medicament | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Thyroid Diseases | 15 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Bronchial Neoplasms | 3 |
| Carcinoma, Bronchogenic | 3 |
| Colonic Neoplasms | 3 |
| Endocrine Gland Neoplasms | 3 |
| Endocrine System Diseases | 3 |
| Head and Neck Neoplasms | 3 |
| Lung Diseases | 3 |
| Lung Neoplasms | 3 |
Trials
Showing 76 to 15 of 15. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.